Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Prescription Drug User Fee Act action date set by FDA for 14 February 2025.
Download (PDF, 201.1KB) -
Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Download (PDF, 207.9KB) -
GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma
Trial unblinded early at an interim analysis based on Independent Data Monitoring Committee recommendation
Download (PDF, 185.7KB) -
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Download (PDF, 126.1KB) -
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF, 136.6KB) -
GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF, 150.6KB) -
Statement: Zantac (ranitidine) litigation
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Download (PDF, 108.6KB) -
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.
Download (PDF, 318.5KB) -
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
EAGLE-1 trial met its primary efficacy endpoint.
Download (PDF, 137.7KB) -
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
Full data set to be presented at an upcoming scientific conference.
Download (PDF, 147.7KB) -
GSK completes acquisition of Aiolos Bio
GSK has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company.
Download (PDF, 119.6KB) -
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Download (PDF, 189.2KB) -
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
Download (PDF, 275.7KB) -
GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration
Shingrix already approved in China for adults aged 50 years and over.
Download (PDF, 145.0KB) -
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma
Results from an interim analysis of the DREAMM-7 phase III head-to-head trial.
Download (PDF, 184.1KB) -
Statement: Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court.
Download (PDF, 108.6KB) -
GSK delivers strong 2023 performance and upgrades growth outlooks
FY 2023 performance highlights
Download (PDF, 942.2KB) -
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
Download (PDF, 167.1KB) -
European Commission authorises GSK’s Omjjara (momelotinib)
First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Download (PDF, 152.5KB) -
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.
Download (PDF, 260.3KB)
